Avalo Therapeutics (AVTX) Total Liabilities (2014 - 2026)

Avalo Therapeutics' Total Liabilities history runs 13 years deep, the most recent figure standing at $31.6 million for Q1 2026.

• Quarterly Total Liabilities rose 98.42% year-over-year to $31.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.6 million (up 98.42% YoY) and the FY2025 annual result came in at $33.4 million, up 88.75% from the prior year.
• Total Liabilities was $31.6 million for Q1 2026 at Avalo Therapeutics, down from $33.4 million in the prior quarter.
• Across five years, Total Liabilities topped out at $224.8 million in Q1 2024 and bottomed at $13.7 million in Q4 2023.
• A 5-year average of $49.6 million and a median of $33.6 million in 2025 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities surged 428.95% — and 2025, when it sank 92.92%.
• Avalo Therapeutics' Total Liabilities stood at $44.3 million in 2022, then tumbled by 69.09% to $13.7 million in 2023, then rose by 29.3% to $17.7 million in 2024, then surged by 88.75% to $33.4 million in 2025, then dropped by 5.52% to $31.6 million in 2026.
• Business Quant data shows AVTX's Total Liabilities at $31.6 million in Q1 2026, $33.4 million in Q4 2025, and $33.6 million in Q3 2025.